Literature DB >> 34021261

A new technological approach in diagnostic pathology: mass spectrometry imaging-based metabolomics for biomarker detection in urachal cancer.

Judith Martha Neumann1, Karsten Niehaus1, Nils Neumann2, Hans Christoph Knobloch3, Felix Bremmer4, Ulrich Krafft5, Udo Kellner6, Peter Nyirády7, Tibor Szarvas5,7, Hanna Bednarz8,9, Henning Reis10.   

Abstract

Urachal adenocarcinomas (UrC) are rare but aggressive. Despite being of profound therapeutic relevance, UrC cannot be differentiated by histomorphology alone from other adenocarcinomas of differential diagnostic importance. As no reliable tissue-based diagnostic biomarkers are available, we aimed to detect such by integrating mass-spectrometry imaging-based metabolomics and digital pathology, thus allowing for a multimodal approach on the basis of spatial information. To achieve this, a cohort of UrC (n = 19) and colorectal adenocarcinomas (CRC, n = 27) as the differential diagnosis of highest therapeutic relevance was created, tissue micro-arrays (TMAs) were constructed, and pathological data was recorded. Hematoxylin and eosin (H&E) stained tissue sections were scanned and annotated, enabling an automized discrimination of tumor and non-tumor areas after training of an adequate algorithm. Spectral information within tumor regions, obtained via matrix-assisted laser desorption/ionization (MALDI)-Orbitrap-mass spectrometry imaging (MSI), were subsequently extracted in an automated workflow. On this basis, metabolic differences between UrC and CRC were revealed using machine learning algorithms. As a result, the study demonstrated the feasibility of MALDI-MSI for the evaluation of FFPE tissue in UrC and CRC with the potential to combine spatial metabolomics data with annotated histopathological data from digitalized H&E slides. The detected Area under the curve (AUC) of 0.94 in general and 0.77 for the analyte taurine alone (diagnostic accuracy for taurine: 74%) makes the technology a promising tool in this differential diagnostic dilemma situation. Although the data has to be considered as a proof-of-concept study, it presents a new adoption of this technology that has not been used in this scenario in which reliable diagnostic biomarkers (such as immunohistochemical markers) are currently not available.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34021261     DOI: 10.1038/s41374-021-00612-7

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  1 in total

1.  Effect of taurine on cell proliferation and apoptosis human lung cancer A549 cells.

Authors:  Shuo Tu; Xia-Li Zhang; Hui-Fang Wan; Yan-Qin Xia; Zhuo-Qi Liu; Xiao-Hong Yang; Fu-Sheng Wan
Journal:  Oncol Lett       Date:  2018-02-13       Impact factor: 2.967

  1 in total
  3 in total

Review 1.  MALDI-MSI Towards Multimodal Imaging: Challenges and Perspectives.

Authors:  Michael Tuck; Florent Grélard; Landry Blanc; Nicolas Desbenoit
Journal:  Front Chem       Date:  2022-05-09       Impact factor: 5.545

Review 2.  New Advances in Tissue Metabolomics: A Review.

Authors:  Michelle Saoi; Philip Britz-McKibbin
Journal:  Metabolites       Date:  2021-09-30

3.  Editorial: Personalized Medicine for Urological Cancers: Targeting Cancer Metabolism.

Authors:  Jennifer H Gunter; Marianna Kruithof-de Julio; Eugenio Zoni
Journal:  Front Oncol       Date:  2022-03-03       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.